Semaglutide is the active ingredient in both Wegovy and Ozempic. It is a GLP-1 (glucagon-like peptide-1) receptor agonist, which means it mimics the action of the GLP-1 hormone that helps regulate blood sugar levels and appetite.

Semaglutide- Compounded medication that we prescribe

Ozempic- Brand name of Semaglutide that is FDA approved for the treatment of Type 2 Diabetes

Wegovy- Brand name of Semaglutide that is FDA approved for the treatment of obesity

Semaglutide promotes weight loss by acting on GLP-1 receptors in the brain to reduce appetite and increase feelings of fullness after meals. It also slows gastric emptying, which makes patients feel fuller longer after meals, stabilizes blood sugar levels, and may directly affect metabolism and fat breakdown. These effects help patients consume fewer calories, manage cravings, and adopt healthier eating behaviors, contributing to significant weight loss over time.

While Semaglutide is a safe therapy approved by the FDA for weight loss, it is not safe if you have any of the following:

• diabetic retinopathy (eye damage resulting from diabetes)

• impaired kidney function

• thyroid cancer

• family history of medullary thyroid carcinoma

• kidney disease (with likely reduction in kidney function)

• pancreatitis (inflammation of the pancreas)

• low blood sugar

• multiple endocrine neoplasia (type 2)

Semaglutide is taken via subcutaneous injection once weekly using a needle and syringe. It can be administered into the abdomen, thigh, or upper arm. Don’t worry, we will provide proper training with your first injection and the needle to so tiny, you can barely feel it!

You only need to take it once a week.

Yes, the pharmacy provides strict storage instructions

There are no fixed guidelines for determining the duration of treatment with this medication. In clinical trials, patients used the medication for 52 to 68 weeks.

Our suggestion is to continue taking the medication until you achieve your desired weight goal.

If you're interested in delving into the clinical trial that resulted in Semaglutide becoming the first weight loss drug approved by the FDA in 15 years, you can access it here. (make ‘here’ a hyperlink) (https://www.nejm.org/doi/10.1056/NEJMoa2032183)

Here’s a brief summary

• The trial lasted approximately 16 months.

• The average reduction in body weight from the start to week 68 (16 months) was −14.9% in the group receiving semaglutide, compared to −2.4% in the placebo group.

• Participants in the semaglutide group experienced a weight loss of −15.3 kg (33.6 lbs), whereas those in the placebo group lost −2.6 kg (5.72 lbs).

• Some participants discontinued the trial due to side effects such as nausea and diarrhea, but these were mostly mild and manageable. (Our providers have observed that these side effects can be significantly reduced by gradually adjusting the medication dosage).

If you live in one of our serving states, schedule your virtual weight loss visit with Women’s Telehealth Solutions today! During the visit, you'll receive:

- A thorough evaluation with measurements

- Review of medical history

- Orders for baseline Lab Work

- Dietary and exercise recommendations

- Access to our secure patient-provider portal for messaging

Your medication, along with needles, will be shipped directly to your home once you start the program.

Doctors, Nurse Practitioners, Physician Assistants

Unfortunately, No, most insurances do not cover semaglutide for the management of obesity and weight management. Women’s Telehealth Solutions does not take insurance.